Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label Read more about Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025 Read more about Krystal Biotech to Present at Cantor Global Healthcare Conference 2025
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer Read more about Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025 Read more about Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025
Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa Read more about Krystal Biotech Announces Approval of VYJUVEK® by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis Read more about Krystal Biotech Announces First Patient Dosed in Phase 1/2 Trial of KB801 for the Treatment of Neurotrophic Keratitis
Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa Read more about Krystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis Bullosa
Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference Read more about Krystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare Conference
Krystal Biotech to Present at BofA Securities 2025 Health Care Conference Read more about Krystal Biotech to Present at BofA Securities 2025 Health Care Conference
Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa Read more about Krystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
